Clinical Trial Update: A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update reporting on the safety and efficacy of Fabrazyme for Fabry disease; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• FABRAZYME (Agalsidase beta)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Fabry Disease | Phase 3 | Status: COMPLETED